Primary and metastatic malignant bone lesions result in significant pain and disability in oncology patients. Targeted bone-seeking radioisotopes including 153Samarium ethylene-diamine-tetramethylene-phosphonic acid (153Sm-EDTMP) have been shown to effectively palliate bone pain, often when external beam radiotherapy (EBRT) is not feasible. However, recent evidence also suggests 153Sm-EDTMP has...

INTRODUCTION The aim of the present study was to compare the therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP in pain palliation in cancer patients with skeletal metastases. MATERIALS AND METHODS Thirty patients (25 M:5 F, mean age: 66.0 ± 14.7 years) of breast/prostate cancer with documented skeletal metastases were recruited prospectively. Twenty patients were considered randomly for tre...

One month later the patient received 4.22 GBq (114 mCi) 153Samarium-EDTMP for palliation of severe bone pain. Post treatment, whole body 153Samarium scan was also a “superscan” showing very similar osseous metastases pattern to the 99mTc-MDP bone scan. Anterior and posterior whole body images 24 hours after intravenous administration of 153Sm-EDTMP demonstrate diffuse osseous metastases in a ve...

the effectiveness of an intervention against cancer cells compared to normal tissue. Although chemotherapy and radiation are common and effective treatment modalities for skeletal neoplasia (1), bone-seeking radioisotopes offer a new opportunity to provide additional benefit via specific targeting of the skeleton and/or bone-forming lesions (e.g. osteoblastic metastases in the skeleton, marrow,...

CONTEXT More than 50% of patients with prostate, breast or lung cancer will develop painful bone metastases. The purpose of treating bone metastases is to relieve pain, reduce the use of steroids and to maintain motion. OBJECTIVE To evaluate the use of samarium-153-EDTMP (153Sm-EDTMP) for the treatment of bone pain secondary to metastases that is refractory to clinical management. TYPE OF S...

BACKGROUND Samarium-153 ethylenediamine tetramethylene phosphoric acid (153Sm-EDTMP) is a radiopharmaceutical that has been used to treat osteosarcoma. The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities. METHODS Patients with ...

Osteoblastic metastases and osteosarcoma can avidly concentrate bone-seeking radiopharmaceuticals. We sought to increase effectiveness of high-dose (153)Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDTMP, Quadramet) on osteosarcomas using a radiosensitizer, gemcitabine. Fourteen patients with osteoblastic lesions were treated with 30 mCi/kg 153Sm-EDTMP. Gemcitabine was administered ...

introduction: nowadays various bone pain palliative therapeutic agents have been developed for bone metastases. among those, 153sm-ethylenediamine tetramethylene phosphonic acid (153sm-edtmp) is the major therapeutic agent which is widely used in the world. in this study, production, quality control and biodistribution studies of this therapeutic radiopharmaceutical have been presented and foll...

Fifteen dogs were referred because of a spontaneous bone tumor, lameness, and local pain. The osteosarcoma diagnosis was established by clinical examination, X-ray, bone scintigraphy, and histological examination of biopsy material. The tumors were located in the extremities (n = 12), scapula (n = 1), maxilla (n = 1), and the frontal bone (n = 1). The dogs were given one to four i.v. injections...

UNLABELLED The aim of this study was to introduce a new quantification method for 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) and 186Re-(tin)1,1-hydroxyethylidene diphosphonate (HEDP) to separately measure bone uptake and soft-tissue retention of these radiopharmaceuticals. METHODS Studies were performed on 23 men and 6 women undergoing radionuclide therapy for palliation of bone p...